EUVIMEDEUVIMED entdecken
Crossref

Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis

Vito Terlizzi, Cristina Fevola, Martina Cecchetti, Alberto Terminiello, Franco Curci, Elisa Bartolini, Chiara Rubino, Mariangela Stinco, Simona Carrera, Paolo Bonomi, Giovanni Taccetti, Zachary M Sellers und 1 weitere

Journal of Cystic Fibrosis · 2025-05 · 24 (3) · 574-580

DOI: 10.1016/j.jcf.2024.12.010 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Cystic Fibrosis, 2025-05. Verfasst von Vito Terlizzi und 12 weiteren Autor:innen. Beteiligte Einrichtung: Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Department of Paediatric Medicine, Florence, Italy. Electronic address: v…. Hauptthemen laut MEDLINE: Cystic Fibrosis, Elasticity Imaging Techniques, Aminophenols, Benzodioxoles. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Elexacaftor-tezacaftor-ivacaftor (ETI) has significantly improved the clinical course of people with cystic fibrosis (pwCF) and eligible CFTR variants. In this study, we prospectively evaluated liver elastography, liver fibrosis indices and liver tests in children with CF aged 6-12 years started on ETI therapy. METHODS: Body mass index, sweat test, percent predicted forced expiratory volume in one second, serum markers of liver injury or portal hypertension, liver fibrosis indices, controlled attenuation parameter and liver stiffness were assessed before starting ETI and three and twelve months post-ETI, according to new international guidelines. RESULTS: 27 children with CF were enrolled, 14 with liver involvement and 13 without liver involvement at baseline. A significant improvement in sweat chloride after ETI was observed in all subjects. In those with liver involvement, liver stiffness significantly decreased at 12 months of ETI, with all individuals achieving normalization or near-normalization of liver stiffness. The majority of individuals with abnormal AST, ALT, GGT, or liver fibrosis indices at baseline experienced normalization by 12 months of ETI (AST: 67%, ALT: 100%, GGT: 50%, APRI: 100%, GPR: 100%). In the no liver involvement group, the only significant change in liver health metrics at 12 months was a significant reduction in platelets (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisElasticity Imaging TechniquesAminophenolsBenzodioxolesQuinolonesLiver CirrhosisPhenylpropionatesIndolesPyrazolesPyrrolidinesPyridinesHumansChildMaleFemaleDrug CombinationsChloride Channel AgonistsProspective StudiesLiver Function TestsHematologic TestsTreatment OutcomeLiverQuinolines

Stichwörter der Autor:innen

CAPCFHBICFLDCFTR modulatorHEMTPediatricsStiffness

Substanzen

AminophenolsBenzodioxolesQuinolonesDrug CombinationsChloride Channel AgonistsPhenylpropionatesIndolesPyrazoleselexacaftor, ivacaftor, tezacaftor drug combinationPyrrolidines

Autor:innen und Institutionen

  • Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Department of Paediatric Medicine, Florence, Italy. Electronic address: vito.terlizzi@meyer.it.
  • Meyer Children's Hospital IRCCS, Cystic Fibrosis Regional Reference Centre, Department of Paediatric Medicine, Florence, Italy.
  • Department of Health Sciences, University of Florence, Florence, Italy; Meyer Children Hospital IRCCS, Florence, Italy.
  • Department NEUROFARBA, University of Florence; Paediatric and Liver Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Paediatric and Liver Unit, Meyer Children's Hospital IRCCS, Florence, Italy.
  • Freelance Statistician, Milan, Italy.

Zitieren

APA

Terlizzi, V., Fevola, C., Cecchetti, M., Terminiello, A., Curci, F., Bartolini, E., Rubino, C., Stinco, M., Carrera, S., Bonomi, P., Taccetti, G., Sellers, Z. M., & Indolfi, G. (2025). Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis. Journal of Cystic Fibrosis, 24(3), 574-580. https://doi.org/10.1016/j.jcf.2024.12.010

Vancouver

Terlizzi V, Fevola C, Cecchetti M, Terminiello A, Curci F, Bartolini E, et al. Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis. Journal of Cystic Fibrosis. 2025;24(3):574-580. doi:10.1016/j.jcf.2024.12.010

BibTeX
@article{Terlizzi2025,
  author = {Terlizzi, Vito and Fevola, Cristina and Cecchetti, Martina and Terminiello, Alberto and Curci, Franco and Bartolini, Elisa and Rubino, Chiara and Stinco, Mariangela and Carrera, Simona and Bonomi, Paolo and Taccetti, Giovanni and Sellers, Zachary M and Indolfi, Giuseppe},
  title = {Effect of elexacaftor-tezacaftor-ivacaftor on liver transient elastography, fibrosis indices and blood tests in children with cystic fibrosis},
  journal = {Journal of Cystic Fibrosis},
  year = {2025},
  volume = {24},
  number = {3},
  pages = {574--580},
  doi = {10.1016/j.jcf.2024.12.010}
}
Kostenlos starten →